Real-World Outcomes

A National Cancer Database analysis revealed racial and ethnic disparities in patients with gastric cancer in the use of preoperative chemotherapy and in outcomes.
Despite significant treatment advancements in the management of multiple myeloma over the last 20 years, racial disparities in health care access and survival continue to exist.
In recent years, there has been a significant increase in hospitalizations, readmissions, and deaths due to immune-related adverse events from immune checkpoint inhibitors, according to a presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium.
A recent survey highlighted the need for educational resources to go further in-depth into immunotherapy science and management strategies for treatment-related adverse events.
The growing use of effective treatment strategies for metastatic cancer in the brain has not been documented in certain patient populations.
Certain subgroups of patients with NSCLC are underrepresented in clinical trials for newly approved PD-1 inhibitors and are needed to inform real-world treatment decisions.
A commonly used gene expression profile test for predicting breast cancer recurrence proves to be less cost-effective in a real-world setting, according to research published in the Journal of Clinical Oncology.
Receiving care in a community setting is associated with a prolonged maintenance treatment in patients with non-Hodgkin lymphoma.
A recently approved second-line therapy is reasonably effective in the treatment of advanced non-small cell lung cancer, according to a recent real-world study.
Differences in health insurance coverage account for about half of the substantial disparity in survival between black and white patients with colorectal cancer.